Search
+
    SEARCHED FOR:

    KITE PHARMA

    Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

    Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?of Gilead Sciences, was partnering with Arcellx ?to jointly develop and sell anito-cel, an experimental CAR-T therapy for multiple myeloma, a type of blood cancer.

    Bear & bull markets going on side by side now; make ROC your top priority: Madhusudan Kela

    Market expert Madhusudan Kela highlights the coexistence of bull and bear markets. He stresses the need to identify good sectors and companies, manage expectations, and prioritize return of capital. Kela also warns against being overly optimistic and cautions investors to be mindful of market corrections and bubbles in specific sectors.

    Only midcap junkies will buy on dips this year: Dipen Sheth, HDFC Securities

    “Building a largecap portfolio requires patience, especially, in stormy times like this.”

    Fosun targets Fortis: A white knight or a dark horse?

    Often known as China's Warren Buffett, Guo Guangchang prefers to be his student instead. His mysterious disappearance last year raised many eyebrows.

    Novartis's $475,000 cancer breakthrough heralds new era of cures

    The U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than expected.

    Gilead to buy Kite for $11.9 billion in cancer drug megadeal

    With Kite, Gilead will gain cancer therapies and experimental drugs in one of the most promising fields in oncology, in addition to its hepatitis C drug franchise.

    The Economic Times
    BACK TO TOP